ENZEEVU Q Code: Q5149

Drug & Product Overview

HCPCS Descriptor Injection, aflibercept-abzv (enzeevu), biosimilar, 1 mg

HCPCS Added Date April 1, 2025

Manufacturer Sandoz

Route of Administration Intravitreal

Generic Status Single-Source; Branded

About ENZEEVU

Enzeevu is a medication aligned to the HCPCS Q Code: Q5149 for billing, pricing, and reimbursement purposes in the United States. Classified under Ophthalmology, it is administered via the intravitreal route and manufactured by Sandoz.

Manufacturers, reach out to us to add more information.

NDC Code Information

No NDC packages are aligned to Q5149 in publicly available CMS files.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
No public NDC alignments

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

ENZEEVU Pricing & Reimbursement

Q5149 Private Payer Reimbursement

$16.67 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Aflibercept Biosimilar Information:

ENZEEVU Approval Date: August 9, 2024

Product Name	HCPCS Code	Active Ingredient	BLA Type
Eylea	J0178	Aflibercept	351(a) Originator Product
Opuviz	Q5153	Aflibercept	351(k) Interchangeable
Yesafili	Q5155	Aflibercept	351(k) Interchangeable
Ahzantive	Q5150	Aflibercept	351(k) Biosimilar
Enzeevu	Q5149	Aflibercept	351(k) Biosimilar
Pavblu	Q5147	Aflibercept	351(k) Biosimilar
Eydenzelt	Q5170	Aflibercept	351(k) Biosimilar

ENZEEVU CPT Administration Codes

CPT Code	Description
67028	Intravitreal injection of a pharmacologic agent (separate procedure) 67028

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

ENZEEVU Medically Unlikely Edits (MUE)

The most billing units of Q5149 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.

Practitioner Office & Hospital Outpatient

4 units / day

= 4 mg per day

MAI 2 · Date of Service Edit: Policy. Absolute per-day limit set by policy or regulation; units above it are not payable, and denials are not appealable on medical-necessity grounds. See all MUE limits →

ENZEEVU Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Neovascular (Wet) Age-Related Macular Degeneration (AMD) Macular Edema Following Retinal Vein Occlusion (RVO) Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Retinopathy of Prematurity (ROP)

Frequently Asked Questions

Is there an available ENZEEVU billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for ENZEEVU.

Are there any available ENZEEVU patient assistance programs?

ENZEEVU patient assistance information can be found through Sandoz. Visit Here →

Where can I find ENZEEVU prescribing information?

ENZEEVU prescribing information can be found at the link below. Visit Here →

Where can I find ENZEEVU side effect information?

A link for ENZEEVU side effect information is not available.

Does billing ENZEEVU require JZ/JW wastage modifiers?

CMS does not include ENZEEVU (Q5149) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q5149. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.